SCORE2 Report 2: Study Design and Baseline Characteristics

• Published in: Ophthalmology (Rochester, Minn.) Vol. 124; no. 2; pp. 245 - 256
• Main Authors: Scott, Ingrid U, VanVeldhuisen, Paul C, Ip, Michael S, Blodi, Barbara A, Oden, Neal L, Figueroa, Maria, Dugel, Pravin U
• Format: Journal Article
• Language: English
• Published: United States 01.02.2017
• Subjects: Aged; Aged, 80 and over; Angiogenesis Inhibitors - therapeutic use; Bevacizumab - therapeutic use; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Macular Edema - drug therapy; Macular Edema - etiology; Macular Edema - physiopathology; Male; Middle Aged; Prospective Studies; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Recombinant Fusion Proteins - therapeutic use; Retinal Vein Occlusion - complications; Retinal Vein Occlusion - drug therapy; Retinal Vein Occlusion - physiopathology; Tomography, Optical Coherence; Visual Acuity - physiology

To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials. Phase III prospective, multicenter, randomized clinical trial designed to assess whet...